CClinicalTrials.gg
RecruitingNCT06137547Updated May 8, 2025

HPI for Prevention of Hypotension During Cardiac Surgery

An interventional study of Hypotension prediction index (HPI) in Cardiac Surgery Patients, sponsored by Mackay Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Mackay Memorial Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hypotension prediction index (HPI) was applied in various types of non-cardiac surgery with convincing benefits of preventing hypotensive events and clinical sequelae. Although HPI was validated in cardiac surgery, its clinical benefits are not proven yet. We aim to evaluate its effects on intraoperative hypotension and postoperative adverse events in cardiac surgery. In this randomized, single-blind trial, we will enroll adults scheduled for elective primary cardiac surgery under general anesthesia. Participants will be randomly assigned to intraoperative HPI-guided or non-HPI-guided hemodynamic management. The primary endpoint is the time-weighted average intraoperative hypotension below a mean arterial pressure threshold of 65 mmHg. The secondary endpoints are postoperative complications.

02

Conditions studied

  • Cardiac Surgery Patients

Browse trials for

Keywords

  • cardiac surgery
  • hypotension prediction index
  • hypotension
  • randomized controlled trial
03

In context

Hypotension

1,003 studies on the registry are indexed under Hypotension; 173 are open to participants now.

This study's planned enrollment of 110 is above the median of 80 across 675 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Mackay Memorial Hospital is the lead sponsor of 118 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adult
  • elective, primary, isolated coronary arterial bypass surgery (CABG) or isolated valve surgery
  • provide inform consent.

Exclusion criteria

Exclusion Criteria:

  • arrhythmia (e.g., atrial fibrillation, atrial flutter)
  • intracardiac shunts
  • preoperative inotropic usage
  • preoperative supportive devices usage (e.g., intra-aortic balloon pump, extracorporeal membrane oxygenation, left ventricular assist device, or right ventricular assist device)
  • receiving urgent or emergent procedures.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    HPI-guided

    The arterial line of patients in HPI-guided arm will be connected to HemoSphere advanced monitoring platform (EV1000), which will provide HPI value calculated with Acumen Hypotension Prediction Index software.

    Device: Hypotension prediction index (HPI)

  • No intervention
    non-HPI-guided

    The arterial line of patients in non-HPI-guided arm will also be connected to HemoSphere advanced monitoring platform (EV1000) and all hemodynamic parameters will be calculated and showed as HPI-guided arm EXCEPT that the HPI value will not be shown on screen.

Interventions

  • DeviceHypotension prediction index (HPI)

    The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.

06

What researchers measure

Primary outcomes

  1. TWA (time-weighted average) of intraoperative hypotension

    Time-weighted average of intraoperative hypotension below 65 mmHg

    Time frame: From induction to the end of surgery. (If cardiopulmonary bypass (CPB) is adopted, the time of CPB will not be counted in)

Secondary outcomes

  1. incidence of hypotension

    Time frame: from induction to the end of surgery (excluding CPB time)

  2. duration of hypotension

    Time frame: from induction to the end of surgery (excluding CPB time)

  3. postoperative complications

    including acute kidney injury, arrhythmia, myocardial infarction determined by levels of cardiac enzymes, stroke, and mortality

    Time frame: after surgery until discharge, assessed up to 30 days

  4. length of ICU stay

    Time frame: after surgery until ICU discharge, assessed up to 30 days

  5. length of hospital stay

    Time frame: after surgery until hospital discahrge, assessed up to 30 days

07

Study locations

1 of 1 sites recruiting
  • Mackay memorial hospital
    Taipei, 104, Taiwan
    • Yingchun Lin, Master · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Not understand the individual patient data (IPD) sharing platform through enough.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06137547
Lead sponsor
Mackay Memorial Hospital
Responsible party
Ying-Chun Lin (Attending physician, Mackay Memorial Hospital) — Principal investigator
First posted
Nov 18, 2023
Start date
Nov 20, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 8, 2025

Study contacts

Ying-Chun Lin, Master
Contact
elegant.beaver@gmail.com
+886-02-25433535 ext. 3009

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion